We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
Read MoreHide Full Article
Key Takeaways
BridgeBio Pharma's Attruby drove strong revenue growth, but the company remains reliant on one product.
BBIO is preparing three potential U.S. launches that could expand its rare disease portfolio.
BBIO trades at a premium valuation as higher costs and execution risks remain key considerations.
BridgeBio Pharma (BBIO - Free Report) has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
The key question is not whether the company has momentum. It does. The question is whether that momentum can keep outpacing the risks tied to product concentration, launch execution and spending.
BBIO Sales Momentum Makes the Bull Case
Attruby gives the bull case its strongest support. The drug generated $362.4 million in U.S. sales in 2025, its first full year on the market, and nearly $181 million in the first quarter of 2026.
First-quarter revenues reached $194.5 million, above the Zacks Consensus Estimate of $179.8 million, as Attruby uptake continued across patient types and provider segments. That launch strength matters because ATTR-CM remains underdiagnosed, leaving room for diagnosed patient growth.
BridgeBio is also preparing for three potential U.S. product launches over the next 12 months. BBP-418 is under FDA review for LGMD2I/R9, encaleret has been submitted for ADH1 and infigratinib is expected to be filed in achondroplasia in the third quarter of 2026.
That pipeline gives BridgeBio a chance to evolve from an Attruby-led company into a broader rare disease platform. Pfizer (PFE - Free Report) remains relevant because its Vyndaqel family is the established competitor in ATTR-CM, keeping BridgeBio’s market-share gains central to the story.
Why BridgeBio Still Looks Execution Heavy
The caution case starts with concentration. Attruby is BridgeBio’s only approved product, making near-term revenues highly dependent on one commercial asset.
That leaves little room for disruption from safety concerns, access hurdles or slower-than-expected prescribing. Even a strong product can underperform if reimbursement, patient identification or physician education lag in rare disease markets.
The same execution burden applies to the pipeline. BBP-418 and encaleret could become first therapies for their target indications, while infigratinib may benefit from oral dosing, but approval alone would not guarantee rapid uptake.
BioMarin Pharmaceutical (BMRN - Free Report) and Ascendis Pharma (ASND - Free Report) illustrate the competitive backdrop in achondroplasia, where BridgeBio would need to position infigratinib against existing injectable options if approved.
Valuation is the clearest reason for patience. BBIO trades at 12.3X forward 12-month enterprise value to sales, far above 2.7X for the Zacks sub-industry, 2.7X for the sector and 4.9X for the S&P 500.
That premium can be justified only if Attruby continues to scale and the next wave of approvals arrives on schedule. The stock has gained 69.4% over the past 12 months, which means investors are already paying for a sizable portion of the growth narrative.
BridgeBio Earnings Show Growth and Cost Pressure
The latest quarter showed why the debate remains balanced. Revenues rose 66.8% year over year, driven by Attruby, but BridgeBio reported a loss of 84 cents per share, wider than the Zacks Consensus Estimate of a loss of 70 cents.
Operating costs climbed to $300.5 million from $221 million a year earlier. Selling, general and administrative expenses rose to $163.9 million as the company supported Attruby's commercialization and prepared for late-stage launches.
Research and development expenses also increased, reaching $126.6 million. The growth is real, but it is not yet translating cleanly into bottom-line improvement.
Why BBIO Merits a Wait-and-See View
The bottom line is that BBIO still looks more like a stock to monitor than chase aggressively after its run. Attruby’s launch supports the bull case, but the premium valuation leaves limited room for launch delays, cost pressure or slower market-share gains.
The stock’s balanced profile fits a Zacks Rank #3 (Hold) discussion rather than a high-conviction buy view. A Zacks Rank #3 indicates a more neutral near-term earnings revision picture, which lines up with the mix of strong sales momentum and execution-heavy risk. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
Key Takeaways
BridgeBio Pharma (BBIO - Free Report) has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
The key question is not whether the company has momentum. It does. The question is whether that momentum can keep outpacing the risks tied to product concentration, launch execution and spending.
BBIO Sales Momentum Makes the Bull Case
Attruby gives the bull case its strongest support. The drug generated $362.4 million in U.S. sales in 2025, its first full year on the market, and nearly $181 million in the first quarter of 2026.
First-quarter revenues reached $194.5 million, above the Zacks Consensus Estimate of $179.8 million, as Attruby uptake continued across patient types and provider segments. That launch strength matters because ATTR-CM remains underdiagnosed, leaving room for diagnosed patient growth.
BridgeBio is also preparing for three potential U.S. product launches over the next 12 months. BBP-418 is under FDA review for LGMD2I/R9, encaleret has been submitted for ADH1 and infigratinib is expected to be filed in achondroplasia in the third quarter of 2026.
That pipeline gives BridgeBio a chance to evolve from an Attruby-led company into a broader rare disease platform. Pfizer (PFE - Free Report) remains relevant because its Vyndaqel family is the established competitor in ATTR-CM, keeping BridgeBio’s market-share gains central to the story.
Why BridgeBio Still Looks Execution Heavy
The caution case starts with concentration. Attruby is BridgeBio’s only approved product, making near-term revenues highly dependent on one commercial asset.
That leaves little room for disruption from safety concerns, access hurdles or slower-than-expected prescribing. Even a strong product can underperform if reimbursement, patient identification or physician education lag in rare disease markets.
The same execution burden applies to the pipeline. BBP-418 and encaleret could become first therapies for their target indications, while infigratinib may benefit from oral dosing, but approval alone would not guarantee rapid uptake.
BioMarin Pharmaceutical (BMRN - Free Report) and Ascendis Pharma (ASND - Free Report) illustrate the competitive backdrop in achondroplasia, where BridgeBio would need to position infigratinib against existing injectable options if approved.
BridgeBio Pharma, Inc. Price and Consensus
BridgeBio Pharma, Inc. price-consensus-chart | BridgeBio Pharma, Inc. Quote
Valuation Leaves BBIO Little Room to Slip
Valuation is the clearest reason for patience. BBIO trades at 12.3X forward 12-month enterprise value to sales, far above 2.7X for the Zacks sub-industry, 2.7X for the sector and 4.9X for the S&P 500.
That premium can be justified only if Attruby continues to scale and the next wave of approvals arrives on schedule. The stock has gained 69.4% over the past 12 months, which means investors are already paying for a sizable portion of the growth narrative.
BridgeBio Earnings Show Growth and Cost Pressure
The latest quarter showed why the debate remains balanced. Revenues rose 66.8% year over year, driven by Attruby, but BridgeBio reported a loss of 84 cents per share, wider than the Zacks Consensus Estimate of a loss of 70 cents.
Operating costs climbed to $300.5 million from $221 million a year earlier. Selling, general and administrative expenses rose to $163.9 million as the company supported Attruby's commercialization and prepared for late-stage launches.
Research and development expenses also increased, reaching $126.6 million. The growth is real, but it is not yet translating cleanly into bottom-line improvement.
Why BBIO Merits a Wait-and-See View
The bottom line is that BBIO still looks more like a stock to monitor than chase aggressively after its run. Attruby’s launch supports the bull case, but the premium valuation leaves limited room for launch delays, cost pressure or slower market-share gains.
The stock’s balanced profile fits a Zacks Rank #3 (Hold) discussion rather than a high-conviction buy view. A Zacks Rank #3 indicates a more neutral near-term earnings revision picture, which lines up with the mix of strong sales momentum and execution-heavy risk. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.